Inventor · disambiguated record
Rita Steeves
Also filed as: STEEVES RITA · STEEVES RITA M
13 granted patents·6 pending applications·401 citations·filing 2004–2024
93Inventor score
Files withACCELERON PHARMA INC6BRIGHAM & WOMENS HOSPITAL INC3IMMUNOGEN INC3STEEVES RITA M3GOLDMAKHER VIKTOR S2
Top patents by PatentIndex Score
19 records- 0198US8163888B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesSTEEVES RITA M·Filed 2007·Granted Apr 24, 2012·101 cites·53 claims
- 0298US8088387B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesSTEEVES RITA M·Filed 2004·Granted Jan 3, 2012·146 cites·143 claims
- 0398US7989598B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2007·Granted Aug 2, 2011·46 cites·53 claims
- 0497US8198417B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesSTEEVES RITA M·Filed 2007·Granted Jun 12, 2012·59 cites·65 claims
- 0596US9809637B2Transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2016·Granted Nov 7, 2017·19 cites·9 claims
- 0690US8137669B2Elimination of heterogeneous or mixed cell population in tumorsGOLDMAKHER VIKTOR S·Filed 2008·Granted Mar 20, 2012·7 cites·5 claims
- 0788US8388960B2Elimination of heterogeneous or mixed cell population in tumorsGOLDMAKHER VIKTOR S·Filed 2011·Granted Mar 5, 2013·7 cites·3 claims
- 0886US10316076B2Transforming growth factor-beta receptor type II fusion polypeptidesACCELERON PHARMA INC·Filed 2017·Granted Jun 11, 2019·3 cites·19 claims
- 0985US8603483B2Anti-integrin immunoconjugates, methods and usesCHEN QIMING·Filed 2005·Granted Dec 10, 2013·8 cites·15 claims
- 1084US11951156B2Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptorBRIGHAM & WOMENS HOSPITAL INC·Filed 2020·Granted Apr 9, 2024·1 cites·17 claims
- 1183US10682392B2Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion proteinBRIGHAM & WOMENS HOSPITAL INC·Filed 2014·Granted Jun 16, 2020·4 cites·11 claims
- 1278US2024366720A1Compositions and methods for treating pulmonary hypertensionBRIGHAM & WOMENS HOSPITAL INC·Filed 2024·Application pending·0 cites
- 1376US2021230252A1Tgf-beta receptor type ii variants and uses thereofACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 1473US11008377B2Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2020·Granted May 18, 2021·0 cites·16 claims
- 1573US10981973B2Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptideACCELERON PHARMA INC·Filed 2019·Granted Apr 20, 2021·0 cites·17 claims
- 1665US2015056199A1Tgf-beta receptor type ii variants and uses thereofACCELERON PHARMA INC·Filed 2014·Application pending·0 cites
- 1764US2006233814A1Elimination of heterogeneous or mixed cell population in tumorsIMMUNOGEN INC·Filed 2006·Application pending·0 cites
- 1863US2012226025A1Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesCHARI RAVI V J·Filed 2012·Application pending·0 cites
- 1951US2014093523A1Anti-Integrin Immunoconjugates, Methods and UsesIMMUNOGEN INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rita Steeves files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →